Where does Achillion Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Achillion Pharmaceuticals, Inc. ranks #4,598 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Achillion Pharmaceuticals, Inc. hold?

Achillion Pharmaceuticals, Inc. holds 76 US utility patents granted between 2015 and 2025, spanning 9 technology areas.

What is Achillion Pharmaceuticals, Inc.'s Innovation Score?

Achillion Pharmaceuticals, Inc. has an Innovation Score of 43.3 out of 100 (top 28% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Achillion Pharmaceuticals, Inc. focus on?

Achillion Pharmaceuticals, Inc.'s top technology area is C07D (Heterocyclic Compounds) with 67 patents, ranking #108 of 3,165 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is Achillion Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Achillion Pharmaceuticals, Inc.'s recent grant velocity is -38% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Achillion Pharmaceuticals, Inc.'s patents?

Achillion Pharmaceuticals, Inc.'s patents average 21.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Achillion Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Achillion Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 76 granted patents across 9 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Achillion ranks #4,598 of 49,997 tracked US assignees by granted-patent volume, with 76 patents across 9 technology areas.

#4,598
of 49,997 US assignees by volume: Top 28%
by Innovation Score (43.3/100): 21.1
avg claims per patent: -38%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R4598 · US Corporation #4,598 · 76 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-DOWN · BOOK-FULL

GRANTS-SMALL 76 grants
TOP-DECILE #4,598/49,997
PHOTO-FINISH Aleddra
CPC-NARROW C07D · 9 areas
INNOV-PAR 43.3/100
CLAIMS-DENSE 21.1 claims/avg
TYPE-USCORP US Corporation
VEL-DOWN -38% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Aleddra Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Achillion’s 43.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 15.0 pts (35%) Velocity 5.1 pts (12%) Breadth 10.6 pts (24%) Claim depth 12.6 pts (29%)

Qualcomm Incorporated · highest

85
Bell Identification… · near

43
Kutta · near

43
Achillion Pharmaceut… · this assignee

43
Cascades Canada ULC · near

43
Yantai Dongxing… · near

43
3D Lighting… · lowest

7

What this shows Achillion's Innovation Score is 43.3/100 (top 28% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Achillion?

Each dot is one of Achillion’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Achillion’s own 21.1 claims/patent is ABOVE the 16.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Achillion vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Achillion's grants concentrate

Achillion Pharmaceuticals, Inc. is a focused PatentsView assignee: 9 CPC subclasses with 88.2% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2017 (13 grants) versus a trough of 3 in 2022. By volume, Achillion sits between Zhejiang Sanhua Automotive Components Co., Ltd. and Biotix, Inc..

Achillion's three-year grant acceleration

From 2019–2021 to 2022–2024, Achillion Pharmaceuticals, Inc. moved from 21 to 16 grants (0.76x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Zhejiang Sanhua A…

77
mcube

77
Alltop (Suzhou)

76
Arcadyan Technolo…

76
Aleddra

76
Aurrion

76
Autonomous Soluti…

76
Biotix

76
Achillion Pharmac… ◀

76

What this shows Achillion holds 76 patents at rank #4,600, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Achillion

By rank, the assignees closest to #4,600 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Achillion's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Achillion, neither rank-band nor same-CPC leaders (those blocks stay above). In C07D (Heterocyclic Compounds), Achillion ranks #108 of 3,165 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (43 here).

Cascades Canada ULC 43 Yantai Dongxing Magnetic Materials Inc. 43 Kutta Technologies, Inc. 43 Bell Identification B.V. 43

Similar claim depth

Nearest assignees by average claims per patent (21.1 here).

MasterCraft Boat Company, LLC 21.1 avg MongoDB, Inc. 21.1 avg Valens Semiconductor Ltd. 21.1 avg Institute for Research in Biomedicine 21.1 avg

Achillion's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

43 Top 28% higher than 72% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Achillion Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	6	7.9%
2016	7	9.2%
2017	13	17.1%
2018	10	13.2%
2019	9	11.8%
2020	6	7.9%
2021	6	7.9%
2022	3	3.9%
2023	7	9.2%
2024	6	7.9%
2025partial year	3	3.9%

Which technologies does Achillion Pharmaceuticals, Inc. patent most?

C07D - Heterocyclic Compounds 67

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 62

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 49

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 47

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 30

C07K - Peptides 8

Y02A - Technologies FOR Adaptation TO Climate Change 8

C07C - Acyclic OR Carbocyclic Compounds 1

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 1

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Achillion Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Achillion Pharmaceuticals, Inc.'s lead technology class is C07D (Heterocyclic Compounds), 88.2% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #4,598 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Achillion Pharmaceuticals, Inc. against Zhejiang Sanhua Automotive Components Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 43.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.